BioSyent Inc. (BIOYF)

OTCMKTS · Delayed Price · Currency is USD
8.21
0.00 (0.00%)
Oct 28, 2024, 4:00 PM EDT
41.07%
Market Cap 95.31M
Revenue (ttm) 24.71M
Net Income (ttm) 5.22M
Shares Out n/a
EPS (ttm) 0.44
PE Ratio n/a
Forward PE n/a
Dividend 0.13 (1.62%)
Ex-Dividend Date Sep 4, 2024
Volume 2,517
Open 8.00
Previous Close n/a
Day's Range 8.00 - 8.21
52-Week Range 5.65 - 8.90
Beta 0.93
Analysts n/a
Price Target n/a
Earnings Date Nov 15, 2024

About BioSyent

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a ... [Read more]

Sector Healthcare
Founded 2006
Country Canada
Stock Exchange OTCMKTS
Ticker Symbol BIOYF
Full Company Profile

Financial Performance

In 2023, BioSyent's revenue was 31.59 million, an increase of 13.12% compared to the previous year's 27.93 million. Earnings were 6.46 million, an increase of 18.35%.

Financial numbers in CAD Financial Statements

News

BioSyent Releases Financial Results for Q2 and H1 2024

MISSISSAUGA, Ontario, Aug. 26, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q2) and six months (H1) ended June 30, 20...

2 months ago - GlobeNewsWire

BioSyent Declares Third Quarter 2024 Dividend

MISSISSAUGA, Ontario, Aug. 26, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend ...

2 months ago - GlobeNewsWire

FAX Capital Files Early Warning Report Regarding Disposition of Common Shares of BioSyent Inc.

TORONTO, July 24, 2024 (GLOBE NEWSWIRE) -- This press release is being disseminated as required by National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting...

3 months ago - GlobeNewsWire

BioSyent In-Licenses Endocrinology Product for Canada

MISSISSAUGA, Ontario, June 12, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSy...

4 months ago - GlobeNewsWire

BioSyent Releases Financial Results for Q1 2024

MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q1) ended March 31, 2024. Key highlights i...

5 months ago - GlobeNewsWire

BioSyent Declares Second Quarter 2024 Dividend

MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend o...

5 months ago - GlobeNewsWire

BioSyent Schedules Q1 2024 Earnings Release for May 16, 2024

MISSISSAUGA, Ontario, May 09, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2024 on T...

6 months ago - GlobeNewsWire

BioSyent to Attend Planet MicroCap Showcase

MISSISSAUGA, Ontario, April 23, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Showcase in Las Vegas, Nevada ...

6 months ago - GlobeNewsWire

BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement

MISSISSAUGA, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioS...

7 months ago - GlobeNewsWire

BioSyent to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference

MISSISSAUGA, Ontario, April 10, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2024 Bloom Burton & Co. Healthcar...

7 months ago - GlobeNewsWire

BioSyent to Present at LD Micro New York Investor Conference

MISSISSAUGA, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that Mr. René Goehrum, President and CEO of BioSyent, will be presenting...

7 months ago - GlobeNewsWire

BioSyent Announces Grant of Restricted Share Units

MISSISSAUGA, Ontario, March 27, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 66,020 Restricted Sh...

7 months ago - GlobeNewsWire

BioSyent Inc. (BIOYF) Q4 2023 Earnings Call Transcript

BioSyent Inc. (BIOYF) Q4 2023 Earnings Call Transcript

8 months ago - Seeking Alpha

BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023

MISSISSAUGA, Ontario, March 13, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December ...

8 months ago - GlobeNewsWire

BioSyent Schedules Fourth Quarter and Full Year 2023 Earnings Release for March 13, 2024

MISSISSAUGA, Ontario, March 06, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended Dec...

8 months ago - GlobeNewsWire

BioSyent Named to 2024 TSX Venture 50

MISSISSAUGA, Ontario, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that it has been named to the 2024 TSX Venture 50 list as one ...

8 months ago - GlobeNewsWire

BioSyent Declares First Quarter 2024 Dividend

MISSISSAUGA, Ontario, Feb. 06, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend ...

9 months ago - GlobeNewsWire

BioSyent Announces Renewal of Normal Course Issuer Bid

MISSISSAUGA, Ontario , Dec. 13, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the Comp...

11 months ago - GlobeNewsWire

BioSyent Announces the Availability of Gelclair® in Canada

MISSISSAUGA, Ontario, Nov. 20, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has commenced the f...

1 year ago - GlobeNewsWire

BioSyent Releases Q3 and YTD 2023 Financial Results

MISSISSAUGA, Ontario, Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q3) and nine months (YTD) ended September...

1 year ago - GlobeNewsWire

BioSyent Declares Fourth Quarter 2023 Dividend

MISSISSAUGA, Ontario, Nov. 15, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend ...

1 year ago - GlobeNewsWire

BioSyent Launches "menopauseinformation.ca" on World Menopause Day

MISSISSAUGA, Ontario, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce the launch of menopauseinformation.ca, a comprehensive online platform design...

1 year ago - GlobeNewsWire

BioSyent Releases Q2 and H1 2023 Financial Results

MISSISSAUGA, Ontario, Aug. 22, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and six months ended June 30, 2023. Key highlight...

1 year ago - GlobeNewsWire

BioSyent Declares Third Quarter 2023 Dividend

MISSISSAUGA, Ontario, Aug. 22, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend ...

1 year ago - GlobeNewsWire

BioSyent Schedules Q2 and H1 2023 Earnings Release for August 22, 2023

MISSISSAUGA, Ontario, Aug. 15, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and six months ended June 30, 2...

1 year ago - GlobeNewsWire